Cargando…
Evaluating the effects of sodium glucose co-transporter -2 inhibitors from a renin–angiotensin–aldosterone system perspective in patients infected with COVID-19: contextualizing findings from the dapagliflozin in respiratory failure in patients with COVID-19 study
Numerous studies demonstrate parallels between CVD, type 2 diabetes mellitus (T2DM) and COVID-19 pathology, which accentuate pre-existing complications in patients infected with COVID-19 and potentially exacerbate the infection course. Antidiabetic drugs such as sodium-glucose transporter-2 (SGLT-2)...
Autores principales: | Moustafa, Diala Alhaj, Imran, Zainab, Ismail, Roua, Rayan, Menatallah, Gadeau, Alain-Pierre, Eldassouki, Hussein, Abdulrahman, Nabeel, Mraiche, Fatima |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Netherlands
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8803405/ https://www.ncbi.nlm.nih.gov/pubmed/35102475 http://dx.doi.org/10.1007/s11033-022-07183-w |
Ejemplares similares
-
Empagliflozin inhibits angiotensin II-induced hypertrophy in H9c2 cardiomyoblasts through inhibition of NHE1 expression
por: Abdulrahman, Nabeel, et al.
Publicado: (2022) -
Impact of renin–angiotensin–aldosterone system inhibitors on COVID-19
por: Matsuzawa, Yasushi, et al.
Publicado: (2022) -
Crosstalk between Sodium–Glucose Cotransporter Inhibitors and Sodium–Hydrogen Exchanger 1 and 3 in Cardiometabolic Diseases
por: Al-Shamasi, Al-Anood, et al.
Publicado: (2021) -
The renin angiotensin aldosterone system and COVID-19
por: Alsufyani, Hadeel A., et al.
Publicado: (2020) -
Renin-Angiotensin-Aldosterone Inhibitors and COVID-19
por: Benenson, Irina, et al.
Publicado: (2020)